Undisclosed PTPN2 inhibitor / Eilean Therap - LARVOL DELTA

Expert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor Program (PRNewswire) - "Expert Systems...announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction....'We're proud to be Eilean's partner & leverage our cutting-edge AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions with an improved safety and tolerability profile'."

Licensing / partnership • Oncology

EILEAN THERAPEUTICS ACQUIRES BEST-IN-CLASS NON-CLINICAL PTPN2 PROGRAM (PRNewswire) - "Eilean Therapeutics LLC...today announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction. Ness is developing best-in-class PTPN2 inhibitors providing an immuno-oncological therapy with an improved safety and tolerability profile...PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens....Ness' lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding > 1000-fold selectivity..."

M&A • Oncology • Solid Tumor

EILEAN THERAPEUTICS ACQUIRES BEST-IN-CLASS NON-CLINICAL PTPN2 PROGRAM (PRNewswire) - "Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, today announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction. Ness is developing best-in-class PTPN2 inhibitors providing an immuno-oncological therapy with an improved safety and tolerability profile."

M&A • Oncology • Solid Tumor